Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.86 USD | +6.77% | -0.72% | +45.52% |
Mar. 19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
Mar. 15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Financials (USD)
Sales 2024 * | 5.67M | Sales 2025 * | 22.22K | Capitalization | 2.09B |
---|---|---|---|---|---|
Net income 2024 * | -175M | Net income 2025 * | -200M | EV / Sales 2024 * | 314 x |
Net cash position 2024 * | 304M | Net cash position 2025 * | 123M | EV / Sales 2025 * | 88,383 x |
P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-10.7
x | Employees | 136 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.64% |
1 day | +6.77% | ||
1 week | -0.72% | ||
Current month | -12.60% | ||
1 month | -12.48% | ||
3 months | +1.05% | ||
6 months | +105.40% | ||
Current year | +45.52% |
Managers | Title | Age | Since |
---|---|---|---|
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
Keith Regnante
DFI | Director of Finance/CFO | 54 | 20-01-31 |
Jennifer Lachey
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 20-12-16 |
Carl Gordon
CHM | Chairman | 59 | 20-02-29 |
Jasbir Seehra
CEO | Chief Executive Officer | 68 | 15-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 57.86 | +6.77% | 291,970 |
24-04-25 | 54.19 | -3.65% | 261,556 |
24-04-24 | 56.24 | +1.90% | 311,717 |
24-04-23 | 55.19 | -1.06% | 478,427 |
24-04-22 | 55.78 | -4.29% | 275,096 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.52% | 2.09B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- KROS Stock